IRX5183 is an orally bioavailable small molecule with a highly selective RARĪ± agonist profile. It is effective in animal models of acute myeloid leukemia and multiple myeloma as monotherapy and in combination with other agents. It has successfully completed phase I clinical trials in 36 patients with solid tumors and leukemias. It has demonstrated activity in acute myeloid leukemia patients as a monotherapy. Current focus of the program is on development of IRX5183 for the treatment of multiple myeloma and acute myeloid leukemias.
Immuno-oncology Autoimmune Therapeutics Neurotherapeutics